Patterson, CJ, Gauthier, S, Bergman, H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ. 1999;160:S1-15.
Chertkow, H. Diagnosis and treatment of dementia: introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. CMAJ. 2008;178:316-321.
Gauthier, S, Patterson, C, Chertkow, H, et al. 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. Can J Neurol Sci. 2012;39:S1-S8.
Assessing dementia: the Canadian consensus. Organizing Committee, Canadian Consensus Conference on the Assessment of Dementia. Can Med Assoc J. 1991;144:851-853.
Dubois, B, Feldman, H, Jacova, C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revisiting the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746.
Dubois, B, Feldman, HH, Jacova, C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9:1118-1127.
McKhann, G, Knopman, D, Chertkow, H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement. 2011;7:263-269.
Albert, M, DeKosky, S, Dickson, D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270 9.
Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280-292.
Burhan, A, Bartha, R, Bocti, C, et al. Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5:S4.
Soucy, J-P, Bartha, R, Bocti, C, et al. Clinical applications of neuroimaging in patients with Alzheimer’s disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5:S3.
Klunk, WE, Engler, H, Nordberg, A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
Jack, CR Jr., Wiste, HJ, Weigand, SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732-1740.
Sperling, RA, Rentz, DM, Johnson, KA, et al. The A4 study: stopping AD before symptoms begin?
Sci Transl Med. 2014;6:228fs13.
Farlow, M, Arnold, SE, van Dyck, CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 2012;8:261-271.
Rinne, JO, Brooks, DJ, Rossor, MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-372.
Keller, D. Finally, a big win for a monoclonal in Alzheimer’s. AD/PD 2015: International Conference on Alzheimer’s and Parkinson’s Diseases 2015 [cited 2015, July 31]. Available from: http://www.medscape.com/viewarticle/841856.
Clark, C, Pontecorvo, M, Beach, T, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669-678.
Wolk, DA, Grachev, ID, Buckley, C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68:1398-1403.
Rowe, CC, Ackerman, U, Browne, W, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129-135.
Ossenkoppele, R, Prins, ND, Pijnenburg, YA, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9:414-421.
Sanchez-Juan, P, Ghosh, PM, Hagen, J, et al. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014;82:230-238.
Rabinovici, G, Rosen, H, Alkalay, A, et al. Amyloid versus FDG PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034-2042.
Wolk, DA, Price, JC, Madeira, C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012;8:389-398.
Bensaïdane, M, Fortin, M, Damasse, G, Chenard, M, Dionne, C. Clinical utility of amyloid imaging in a complex case of corticobasal syndrome presenting with psychiatric symptoms. J Neurol Disord. 2014;2:2.
Grundman, M, Pontecorvo, MJ, Salloway, SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimers Dis Assoc Disord. 2013;27:4-15.
Zannas, AS, Doraiswamy, PM, Shpanskaya, KS, et al. Impact of 18F-florbetapir PET imaging of beta-amyloid neuritic plaque density on clinical decision-making. Neurocase. 2014;20:466-473.
Mitsis, E, Bender, H, Kostakoglu, L, et al. A consecutive case series experience with [18F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener. 2014;9:10.
Bensaïdane MR, Beauregard JM, Poulin S, et al. (forthcoming). Clinical utility of amyloid PET Imaging in the differential diagnosis of atypical dementias and its impact on caregivers. J Alzheimers Dis. 2016.
Pike, K, Savage, G, Villemagne, V, et al. Beta-amyloid imaging and memory in nondemented individuals: evidence for preclinical Alzheimer’s disease. Brain. 2007;130:2837-2844.
Rowe, C, Ellis, K, Rimajova, M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-1283.
Jack, CR Jr., Wiste, HJ, Weigand, SD, et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13:997-1005.
Petersen, RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
Petersen, RC. MIld cognitive impairment or questionable dementia?
Arch Neurol. 2000;57:643-644.
Kantarci, K, Lowe, V, Przybelski, SA, et al. APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology. 2012;78:232-240.
Mormino, EC, Betensky, RA, Hedden, T, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379-1385.
Dickerson, BC, Bakkour, A, Salat, DH, et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497-510.
Roe, CM, Fagan, AM, Grant, EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80:1784-1791.
Klunk, WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32:S20-S36.
Ostrowitzki, S, Deptula, D, Thurfjell, L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198-207.
Pontecorvo, M, Mintun, M. PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer’s disease. Alzheimers Res Ther. 2011;3:11.
Wolk, DA, Price, JC, Saxton, JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557-568.
Okello, A, Koivunen, J, Edison, P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73:754-760.
Ellis, KA, Lim, YY, Harrington, K, et al. Decline in cognitive function over 18 months in healthy older adults with high amyloid-beta. J Alzheimers Dis. 2013;34:861-871.
Rabinovici, GD, Jagust, WJ, Furst, AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64:388-401.
de Souza, LC, Corlier, F, Habert, MO, et al. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer’s disease. Brain. 2011;134:2036-2043.
Laforce, R, Buteau, J, Paquet, N, Verret, L, Houde, M, Bouchard, R. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. Am J Alzheimers Dis Other Dement. 2010;25:324-332.
Ratnavalli, E, Brayne, C, Dawson, K, Hodges, JR. The prevalence of frontotemporal dementia. Neurology. 2002;58:1615-1621.
Alladi, S, Xuereb, J, Bak, T, et al. Focal cortical presentations of Alzheimer’s disease. Brain. 2007;130:2636-2645.
Villemagne, VL, Ong, K, Mulligan, RS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210-1217.
Beach, TG, Monsell, SE, Phillips, LE, Kukull, W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266-273.
Ossenkoppele, R, Jansen, WJ, Rabinovici, GD, et al. Prevalence of amyloid pet positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939-1950.
Cselényi, Z, Jönhagen, ME, Forsberg, A, et al. Clinical validation of 18F-AZD4694, an amyloid-β–specific PET radioligand. J Nucl Med. 2012;53:415-424.
Juréus, A, Swahn, BM, Sandell, J, et al. Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand. J Neurochem. 2010;114:784-794.
Rowe, CC, Pejoska, S, Mulligan, RS, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med. 2013;54:880-886.
Lee, JH, Kim, SH, Kim, GH, et al. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology. 2011;77:18-25.
Johnson, KA, Gregas, M, Becker, JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229-234.
Maetzler, W, Liepelt, I, Reimold, M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009;34:107-112.
Johnson, K, Minoshima, S, Bohnen, N, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9:1-15.
Jagust, WJ. Amyloid imaging: liberal or conservative? Let the data decide. Arch Neurol. 2011;68:1377-1378.
Johnson, KA, Minoshima, S, Bohnen, NI, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med. 2013;54:1011-1013.
Curtis, C, Gamez, JE, Singh, U, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287-294.
Sabri, O, Sabbagh, MN, Seibyl, J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11:964-974.
Guyatt, GH, Oxman, AD, Vist, GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926.
Harkins, K, Sankar, P, Sperling, R, et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7:26.
Laforce, R, Rabinovici, G. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther. 2011;3:31.
Ducharme, S, Guiot, M-C, Nikelski, J, Chertkow, H. Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease?
JAMA Neurol. 2013;70:912-914.
Bohnen, N, Djang, D, Herholz, K, Anzai, Y, Minoshima, S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med. 2012;53:59-71.
Jagust, W, Reed, B, Mungas, D, Ellis, W, Decarli, C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
Mosconi, L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486-510.
Mosconi, L, Tsui, WH, Herholz, K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49:390-398.
Silverman, D, Small, G, Chang, C, et al. Positron emission tomography in evaluation of dementia - regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127.
Silverman, DH, Gambhir, SS, Huang, HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med. 2002;43:253-266.
Jack, C, Wiste, H, Vemuri, P, et al. Brain beta-amyloid measure and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain. 2010;133:3336-3348.
Bateman, RJ, Xiong, C, Benzinger, TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795-804.
Fagan, AM, Head, D, Shah, AR, et al. Decreased CSF Aβ42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176-183.
Palmqvist, S, Zetterberg, H, Blennow, K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282-1289.
Landau, SM, Lu, M, Joshi, AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol. 2013;74:826-836.
Hampel, H, Bürger, K, Teipel, SJ, Bokde, AL, Zetterberg, H, Blennow, K. Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease. Alzheimers Dement. 2008;4:38-48.
Mulder, C, Verwey, NA, van der Flier, WM, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56:248-253.
Rosa-Neto, P, Hsiung, G-Y, Masellis, M, on behalf of the CCDTD4 participants. Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. Alzheimers Res Ther. 2013;5:S8.
Hampel, H, Teipel, SJ. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord. 2004;17:350-354.
Bian, H, Van Swieten, JC, Leight, S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70:1827-1835.
Borroni, B, Malinverno, M, Gardoni, F, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology. 2008;71:1796-1803.
Kapaki, E, Paraskevas, GP, Papageorgiou, SG, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2008;22:47-53.
Hu, WT, Watts, K, Grossman, M, et al. Reduced CSF p-tau181 to tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81:1945-1952.
Bibl, M, Mollenhauer, B, Lewczuk, P, et al. Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord. 2011;31:37-44.
Landau, SM, Mintun, MA, Joshi, AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578-586.